Ligand Pharmaceuticals Incorporated
LGND
$159.76
$0.970.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 109.34% | -149.28% | -270.93% | 30.19% | -2,366.86% |
| Total Depreciation and Amortization | -8.56% | -5.20% | -3.24% | -4.57% | -2.28% |
| Total Amortization of Deferred Charges | -10.50% | 25.80% | 27.01% | 111.68% | 16.73% |
| Total Other Non-Cash Items | -86.60% | 115.48% | 1,162.12% | -7.28% | 1,079.63% |
| Change in Net Operating Assets | 18.91% | -162.70% | 172.55% | 134.18% | -38.97% |
| Cash from Operations | 18.66% | -235.84% | 253.02% | 377.77% | 16,336.59% |
| Capital Expenditure | 47.55% | -103.81% | -70.74% | -22.38% | -100.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 80.77% | 239.18% | -284.22% | -433.17% | -800.49% |
| Cash from Investing | 80.52% | 229.64% | -275.56% | -138.46% | -824.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -75.00% | -40.00% | -20.00% | 28.57% | 99.99% |
| Issuance of Common Stock | -13.75% | -72.41% | 765.42% | 531.68% | 4.48% |
| Repurchase of Common Stock | -- | -189.04% | -652.92% | -21.36% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 12,219.30% | -73.17% | -3,498.31% | -- | -- |
| Cash from Financing | 57.99% | -138.97% | 283.59% | 1,584.40% | 114.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 161.59% | -189.61% | 180.62% | 629.64% | 46.99% |